The United States (US) Food and Drug Administration (FDA) has approved the anti-CD38 monoclonal antibody, isatuximab-irfc, in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for transplant.^1,2 The approval was based on results from the phase 3 IMROZ study which showed that isatuximab combined with bortezomib, lenalidomide, and dexamethasone (VRd) significantly enhanced progression-free survival (PFS) compared to standard-of-care in newly diagnosed adult patients ineligible for autologous stem cell transplant (ASCT).¹